Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 386

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 386
---
 consolidated balance sheet at its fair value equal to 10% of the second closing amount, or $2.3 million. The remaining proceeds from the first closing were allocated to the shares of common stock issued in the first closing and to the warrants as such instruments are equity-classified. The future right was subject to remeasurement at each reporting date and the Company used the Monte Carlo simulation method to determine fair value of approximately $3.8 million as of December 31, 2023 and zero as of December 31, 2024 as the second closing did not occur. The Company incurred insignificant issuance costs related to the Private Placement.

| 9. | Licensing Revenue Agreement |

Merck In June 2023, the Company achieved a development milestone pursuant to the Merck Neuromuscular License Agreement, which triggered a $5.0 million payment. This collaboration focused on the discovery and development of novel candidates for the treatment of ALS. Merck will continue to advance the research program for the ALS pipeline, one of the two pipeline programs licensed under the Merck Neuromuscular License Agreement. As a result, the Company is eligible to receive up to an additional $255.0 million in development milestones, sales milestones and royalties on net sales. Following this milestone, Merck will assume sole responsibility for all future development and commercialization for the ALS program. The Company recognized revenue of zero for the year ended December 31, 2024 and one-timelicensing revenue of $5.0 million for the year ended December 31, 2023 under the Merck Neuromuscular License Agreement. 10. Collaboration Agreement The following table shows the activity for the Company’s collaboration revenue agreement and deferred revenue (in thousands):

|                                             |     | December 31,   
 2024           
 (in thousands) |   |     | 2023 |      |   |
|:--------------------------------------------|:----|:---------------|:--|:----|:-----|-----:|:--|
| Balance as of beginning of period           |     | $              | — |     | $    |  442 |   |
| Decrease for provision of research services |     |                | — |     |      | (442 | ) |
| Balance as of end of period                 |     | $              | — |     | $    |    — |   |

Merck In connection with the Kineta-Yumanity Merger, the Company became the successor in interest to the Mer